Better Health for All

NovoCure's core business, Tumor Treating Fields (TTFields) therapy, is a novel treatment for aggressive cancers, with over 35,000 patients treated through January 2025.

Real-world data indicates improved survival outcomes for glioblastoma patients with increased TTFields usage, and Optune Lua demonstrated a median overall survival of 18.2 months for malignant pleural mesothelioma patients. The company's products do not have significant negative health impacts. However, safety data for Optune Lua shows skin irritation in 71% of patients (66% mild-to-moderate, 5% severe), and Optune has common adverse events (≥10%) including thrombocytopenia, nausea, and fatigue. While there have been zero recalls, fatalities, or FDA enforcement actions, the high rate of device-related side effects is notable. The company has not increased prices since 2014, excluding federal adjustments, and provided over $3 million in charitable care in 2022. It is contracted with 80% of patients' insurers and offers financial coordinators to minimize patient costs. NovoCure focuses on aggressive cancers, which often affect vulnerable populations, and provides treatment at no charge to patients meeting certain criteria under its charitable care policy. The company actively monitors and evaluates adverse events, requires employees to report concerns, and has robust processes for handling complaints, including a compliance hotline. In 2024, NovoCure invested $210 million in R&D. The company is transitioning its Device Support Specialists vehicle fleet to hybrid vehicles, acquiring 30 in 2022, and recycles all electronic waste from its U.S. Operations Center. NovoCure partners with patient advocacy organizations to address health equity and inclusivity. It offers comprehensive global benefits for employee wellbeing, including mental health support, and has a training and development center. The company holds ISO 13485 and ISO 27001 certifications, had no material privacy or security breaches in 2022, and complies with GDPR, HIPAA, CCPA, and CPRA. All Novocure-sponsored clinical trials adhere to applicable laws, regulations, and ethical standards. The company offers educational support for healthcare professionals and patients, including in-service programs and access to the LinkedIn Learning platform.

Fair Money & Economic Opportunity

NovoCure Limited is an oncology company focused on medical devices, not a financial institution.

The company does not offer lending, deposit services, or consumer credit products. Therefore, KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives (financial), data accessibility (financial), fair lending compliance, wealth building outcomes (customer credit/savings), profit reinvestment (community finance), financial literacy initiatives (financial), debt burden ratio, geographic inclusion (banking deserts), and product simplicity (financial products), are not applicable to its core business model. No specific, concrete data points were found in the provided articles that directly map to the quantitative thresholds of these KPIs as defined for financial services.

Fair Pay & Worker Respect

For the 2024 fiscal year, NovoCure's CEO pay ratio was 11:1, with the CEO's total compensation at $1,539,088 and the median employee pay at $141,515.

No other quantitative data for the remaining KPIs related to Fair Pay & Worker Respect was found in the provided articles.

Fair Trade & Ethical Sourcing

No specific, concrete evidence was found in the provided articles to assess NovoCure Limited against any of the Fair Trade & Ethical Sourcing KPIs. The articles contained financial and operational data,

details on a Comprehensive Compliance Program focused on pharmaceutical regulations and interactions with healthcare professionals, and general statements about a lack of data for ethical sourcing metrics. Therefore, all KPIs related to fair trade certification, audit frequency, forced/child labor incidents, traceability, remediation speed, ethical clause coverage, materials risk, and supplier diversity spend have been omitted.

Honest & Fair Business

NovoCure has a Compliance Hotline (+1 855-379-1486, online) with anonymous reporting options, allowing reports to be directed to the Chief Compliance Officer, a manager, HR, Senior Management, or General Counsel.

The company also has an anti-corruption policy as part of its Code of Conduct, which incorporates the AdvaMed and MedTech Europe codes and is tailored to OIG Guidance. This policy includes an annual spending limit of $2500 for gifts to healthcare professionals in California. However, the articles do not provide details on the frequency or effectiveness of anti-corruption training.

Kind to Animals

NovoCure conducts preclinical studies that include in vivo (animal) studies on mice, rats, rabbits, sheep, and pigs to assess the safety and effectiveness of its Tumor Treating Fields (TTFields) therapy.

Specifically, rabbits were used in pre-clinical trials for a kidney model, with trials extending up to 5 weeks. However, the provided articles do not offer quantitative data on the number of animals used annually, nor do they detail the extent to which non-animal testing methods are employed or replace animal testing. There is no information regarding cruelty-free certifications, humane certifications for operations, wildlife conservation impact, ethical input substitution, animal-related supplier audits for welfare compliance, cage-free sourcing, or investment in animal-free R&D. The company's animal testing policy is not explicitly stated, and there is no evidence of participation in animal-free R&D collaborations or public policy engagement related to animal welfare.

No War, No Weapons

The provided article is a privacy notice for Novocure Limited and details how the company collects, processes, and shares personal data.

It does not contain any information, quantitative data, or specific facts relevant to the company's involvement with arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding initiatives, or any other criteria related to the 'No War, No Weapons' ethical value. Therefore, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

No specific quantitative data was found in the provided articles to assess NovoCure Limited against the defined Planet-Friendly Business KPIs. While some general sustainable practices are mentioned, such as the use of LED lighting, energy-efficient HVAC systems, recycling programs, and hybrid vehicles, these do not provide the precise metrics required by the rubric (e.g., percentage of renewable energy, waste diversion rates, or specific emissions data).

The new global headquarters in Baar, Switzerland, features rooftop solar panels and a reversible air-to-water heat pump, but no company-wide percentage of renewable energy use is provided. Therefore, all KPIs have been omitted due to a lack of concrete, quantifiable evidence.

Zero Waste & Sustainable Products

No specific, quantitative data or concrete facts regarding NovoCure's waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education could be found in the provided articles.

The company's 2024 Corporate Responsibility Report and other ESG summaries explicitly state the absence of relevant metrics for these areas.